TY - JOUR
T1 - How different is invasive fusariosis in pediatric patients than in adults? A systematic review
AU - Rossato, Luana
AU - Carlesse, Fabianne
AU - Nobrega De Almeida, João
AU - Kontoyiannis, Dimitrios P.
AU - Colombo, Arnaldo Lopes
N1 - Funding Information:
F.C. received educational grants from Pfizer, United Medical and Astellas. DPK reports research support from Astellas Pharma and honoraria for lectures from Merck & Co, Gilead, and United Medical. He has served as a consultant for Astellas Pharma, Cidara, Pulmocide, and Mayne Pharma. A.L.C. has received honoraria from Pfizer, United Medical, Eurofarma, MSD, TEVA.
Funding Information:
J.N.A.J. has received a research grant from FAPESP (grant 2018/19347–4). A.L.C. received grants from CNPq (grant 307510/2015-8) and FAPESP (grant 2017/02203-7).
Publisher Copyright:
© 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - PURPOSE of reviewTo investigate the peculiarities of invasive fusariosis (IF) in pediatric patients.MethodsWe conducted a systematic literature review to identify human cases of locally invasive and systemic fusariosis documented in children (up to 18 years) published between 1973 (first case report) and 2021.Recent findingsOne hundred and six cases were retrieved, and hematologic malignancy was reported in 64% (68/106) of the cases. The most frequent anatomic sites involved were skin 66% (70/106), blood 47% (50/106), and lungs 35% (37/106), bone and joint (8%, 09/106), and eye/central nervous system involvement (8%, 9/106). Fusarium solani, followed by Fusarium oxysporum, were the most commonly reported species. In disseminated fusariosis, relapsed or refractory baseline disease (P < 0.001, OR=10.555, CI 95% 3.552-31.365) was associated with poor outcome, whereas voriconazole-based therapy was associated with better prognosis (P = 0.04, OR = 0.273, CI 95% 0.076-0.978).SummaryHematologic malignancies and solid tumors requiring intensive immunosuppression are the main conditions related to IF in children where other organs than skin, blood, and lungs were frequently involved. Voriconazole therapy appears to be also effective in children with IF, despite the wide pharmacokinetic variability of this triazole in pediatric patients.
AB - PURPOSE of reviewTo investigate the peculiarities of invasive fusariosis (IF) in pediatric patients.MethodsWe conducted a systematic literature review to identify human cases of locally invasive and systemic fusariosis documented in children (up to 18 years) published between 1973 (first case report) and 2021.Recent findingsOne hundred and six cases were retrieved, and hematologic malignancy was reported in 64% (68/106) of the cases. The most frequent anatomic sites involved were skin 66% (70/106), blood 47% (50/106), and lungs 35% (37/106), bone and joint (8%, 09/106), and eye/central nervous system involvement (8%, 9/106). Fusarium solani, followed by Fusarium oxysporum, were the most commonly reported species. In disseminated fusariosis, relapsed or refractory baseline disease (P < 0.001, OR=10.555, CI 95% 3.552-31.365) was associated with poor outcome, whereas voriconazole-based therapy was associated with better prognosis (P = 0.04, OR = 0.273, CI 95% 0.076-0.978).SummaryHematologic malignancies and solid tumors requiring intensive immunosuppression are the main conditions related to IF in children where other organs than skin, blood, and lungs were frequently involved. Voriconazole therapy appears to be also effective in children with IF, despite the wide pharmacokinetic variability of this triazole in pediatric patients.
UR - http://www.scopus.com/inward/record.url?scp=85121626176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121626176&partnerID=8YFLogxK
U2 - 10.1097/QCO.0000000000000776
DO - 10.1097/QCO.0000000000000776
M3 - Review article
C2 - 34751181
AN - SCOPUS:85121626176
SN - 0951-7375
VL - 34
SP - 619
EP - 626
JO - Current opinion in infectious diseases
JF - Current opinion in infectious diseases
IS - 6
ER -